Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8866352 | 0.82 | PDE7A (0.62) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL11632423 | 0.81 | VCAM1 (0.47) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL11660837 | 0.79 | PDE7A (0.50) | MAPTLMNAMEN1KMT2APDE7A | |
| SCHEMBL9132890 | 0.78 | PDE7A (0.58) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL29669365 | 0.77 | KDM4E (0.62) | MAPTLMNAMEN1KMT2ACYP1A2 | |
| SCHEMBL4011637 | 0.77 | KDM4E (0.62) | MAPTLMNAMEN1KMT2ACYP1A2 | |
| SCHEMBL11091201 | 0.77 | MEN1 (0.59) | MAPTLMNAMEN1KMT2APDE7A | |
| SCHEMBL7606463 | 0.76 | PDE7A (0.67) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL2418894 | 0.76 | SMN1; SMN2 (0.52) | MAPTSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL20379380 | 0.76 | MAPT (0.52) | MAPTSMN1; SMN2LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012134-A1 | Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists | CURTIS NEIL ROY | 2009-01-08 | — | — | US | disclosed |
| EP-1866300-A1 | ARYLSULFONYL BENZOFUSED HETEROCYCLES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006100519-A1 | ARYLSULFONYL BENZOFUSED HETEROCYCLES AS 5-HT2A ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| US-5684198-A | N-ARYL-2-HYDROXYPROPANAMIDES | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1997-11-04 | — | — | US | disclosed |
| US-5567735-A | CELL POTASSIUM CHANNEL MODULATOR FOR TREATING ASTHMA | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-22 | — | — | US | disclosed |
| US-5565477-A | TREATMENT OF URINARY INCONTINENCE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-15 | — | — | US | disclosed |
| US-5565465-A | TREATMENT OF URINARY INCONTINENCE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-15 | — | — | US | disclosed |
| EP-0524781-B1 | Therapeutic amides | ZENECA LTD (GB) | 1996-03-27 | — | — | EP | disclosed |
| US-5474999-A | Useful in treatment of urinary incontinence | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-12-12 | — | — | US | disclosed |
| US-5382598-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-01-17 | — | — | US | disclosed |
| US-5272163-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-21 | — | — | US | disclosed |
| EP-0524781-A1 | Therapeutic amides | ZENECA LIMITED (GB) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012134-A1 | Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists | HTR2A, HTR2C, HTR2B | MAPT 2214/4885SMN1; SMN2 483/4885LMNA 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.